TAE LIFE SCIENCES

Investors & News

2020 | Market Watch

TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.

TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy

BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.

2019 | PR Newswire

TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform

Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.

TLS in the News

Events

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.

$30M for Cancer-Focused TAE Life Sciences

$30M for Cancer-Focused TAE Life Sciences

HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.

TAE Raises $40M To Develop New Targeted Radiotherapy

TAE Raises $40M To Develop New Targeted Radiotherapy

Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.

$40 Million for Boron Neutron Capture Therapy

$40 Million for Boron Neutron Capture Therapy

TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.

A Surprise Application To Cancer

A Surprise Application To Cancer

There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.

TAE Life Sciences Announces $40 Million In Venture Capital

TAE Life Sciences Announces $40 Million In Venture Capital

BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy. The procedure has already been tested in Japan, the United States and other locales.

TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding

TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding

TAE Life Sciences is the first to license TAE Technologies’ accelerator-based neutron beam technology for clinical investigation of Boron Neutron Capture Therapy (BNCT).

JASTRO 2020

JASTRO 2020

October 1-3, 2020

Sapporo, Japan
ASTRO Annual Meeting 2020

ASTRO Annual Meeting 2020

October 25-28, 2020

Miami Beach, FL